Logo

ADTX

Aditxt, Inc.

ADTX

Aditxt, Inc. • NASDAQ
$3.80 ▲ 21.02% (+0.66)
Market Cap $81757
52w High $10452.50
52w Low $2.40
Dividend Yield 0%
P/E 0
Volume 24.96M
Outstanding Shares 21.52K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $748 ▼ $3.073M ▼ $-24.045M ▼ -3.215M% ▼ $-548.78 ▼ $-23.964M ▼
Q2-2025 $1.004K ▼ $6.085M ▲ $-7.257M ▼ -722.79K% ▼ $-390.17 ▲ $-6.068M ▼
Q1-2025 $1.018K ▼ $5.608M ▲ $-5.71M ▼ -560.934K% ▼ $-917.004 ▲ $-5.525M ▼
Q4-2024 $3.175K ▼ $5.583M ▲ $-5.227M ▲ -164.618K% ▼ $-4.554K ▲ $-5.07M ▼
Q3-2024 $6.854K $4.24M $-6.941M -101.262K% $-3.138M $-4.552M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $163.041K ▼ $11.8M ▼ $20.659M ▼ $-7.733M ▼
Q2-2025 $323.679K ▼ $32.691M ▲ $20.696M ▲ $12.959M ▼
Q1-2025 $476.416K ▼ $31.222M ▼ $15.458M ▼ $16.589M ▲
Q4-2024 $833.031M ▲ $32.144M ▲ $23.858M ▼ $8.87M ▲
Q3-2024 $328.596K $29.839M $25.39M $4.712M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-24.45M ▼ $-2.345M ▲ $2.425M ▲ $2.184M ▼ $-160.638K ▼ $-2.345M ▲
Q2-2025 $-7.396M ▼ $-2.385M ▲ $-2.425M ▼ $4.657M ▼ $-152.737K ▲ $-2.385M ▲
Q1-2025 $-5.71M ▼ $-11.713M ▼ $0 ▲ $11.357M ▲ $-356.615K ▼ $-11.713M ▼
Q4-2024 $-5.547M ▲ $-6.147M ▼ $-2.74M ▼ $9.391M ▲ $504.435K ▲ $-6.147M ▼
Q3-2024 $-6.98M $-2.364M $-1.26M $3.862M $237.373K $-2.364M

Five-Year Company Overview

Income Statement

Income Statement ADTX has been a pure development-stage biotech: it has not generated meaningful revenue for several years and has consistently reported operating and net losses. The losses themselves look relatively small in absolute terms, but the extremely wild swings in per‑share figures mainly reflect repeated reverse stock splits rather than business improvement. In practical terms, the income statement shows a company still spending on research, development, and overhead without any commercial products yet to offset those costs.

Balance Sheet

Balance Sheet The balance sheet is very thin, with only a small amount of total assets and limited cash, alongside a modest but noticeable build-up of debt. Equity is also small, which means the financial cushion against setbacks is limited. The history of multiple large reverse stock splits suggests that the company has repeatedly issued shares to stay funded, leading to heavy dilution over time. Overall, the balance sheet points to a fragile financial position that depends heavily on ongoing access to capital markets.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting steady cash burn to fund R&D and corporate expenses. There is virtually no spending on long‑term assets, which fits a lean, research‑focused biotech model but also underscores that all funding is going into keeping the pipeline moving rather than building physical infrastructure. With no incoming operating cash, the company remains reliant on external financing to support its development plans and cover its ongoing burn.

Competitive Edge

Competitive Edge ADTX aims to position itself in a promising niche: precisely modulating and monitoring the immune system while also offering advanced diagnostics. Its approach is differentiated by in‑body immune “retraining” (rather than complex cell therapies) and by pairing therapies with immune monitoring and early-detection tests. A sizeable patent estate and proprietary diagnostic platforms provide some protection. However, the company is up against much larger, better‑funded competitors in both therapeutics and diagnostics, and it has not yet proven its approach in late‑stage trials or at commercial scale, so its competitive edge is still largely theoretical and untested in the market.

Innovation and R&D

Innovation and R&D The core of ADTX’s story is innovation. Through Adimune, it is developing DNA‑based therapies intended to “teach” the immune system to tolerate specific targets in autoimmune disease and transplantation, potentially avoiding broad immune suppression. Through Pearsanta, it is advancing immune monitoring, early cancer detection using mitochondrial DNA, and very early risk detection using DNA adducts. These platforms could be powerful if they show strong clinical and real‑world performance. That said, most programs are early‑stage, with key human trials and diagnostic launches still ahead, so scientific, regulatory, and execution risks remain high.

Summary

ADTX is a highly speculative, early‑stage biotech with an ambitious technology vision but a very lean financial base and no recurring revenue. The company’s value proposition rests on its immune modulation platform and its integrated diagnostics strategy, both protected by substantial intellectual property but still awaiting clinical and commercial proof. Financial statements highlight ongoing cash burn, a thin balance sheet, reliance on share issuance, and multiple reverse splits, all of which underscore funding risk and shareholder dilution. Going forward, the main things to watch are: progress and results from first‑in‑human trials of its lead therapy, the commercial rollout and potential separation of its diagnostics arm, and its ability to secure stable financing without overly diluting existing holders.

NEWS

November 18, 2025 · 8:00 AM UTC

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Read more

October 29, 2025 · 4:30 PM UTC

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Read more

October 27, 2025 · 8:30 AM UTC

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Read more

October 20, 2025 · 4:19 PM UTC

Evofem Announces Voting Results from Special Meeting of Stockholders

Read more

September 11, 2025 · 9:18 AM UTC

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Read more